<?xml version='1.0' encoding='utf-8'?>
<document id="30733676"><sentence text="Enhanced Anti-diabetic Effect of Berberine Combined With Timosaponin B2 in Goto-Kakizaki Rats, Associated With Increased Variety and Exposure of Effective Substances Through Intestinal Absorption."><entity charOffset="33-42" id="DDI-PubMed.30733676.s1.e0" text="Berberine" /><entity charOffset="57-71" id="DDI-PubMed.30733676.s1.e1" text="Timosaponin B2" /><pair ddi="false" e1="DDI-PubMed.30733676.s1.e0" e2="DDI-PubMed.30733676.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30733676.s1.e0" e2="DDI-PubMed.30733676.s1.e1" /></sentence><sentence text="Objective: Inspired by the traditionally clinical application of herb pair Zhimu-Huangbo to treat diabetes, a combination of plant ingredients, timosaponin B2 (TB-2) and berberine (BBR), was evaluated for their anti-diabetic efficacy and cooperative mechanisms"><entity charOffset="144-158" id="DDI-PubMed.30733676.s2.e0" text="timosaponin B2" /><entity charOffset="160-164" id="DDI-PubMed.30733676.s2.e1" text="TB-2" /><entity charOffset="170-179" id="DDI-PubMed.30733676.s2.e2" text="berberine" /><entity charOffset="181-184" id="DDI-PubMed.30733676.s2.e3" text="BBR" /><pair ddi="false" e1="DDI-PubMed.30733676.s2.e0" e2="DDI-PubMed.30733676.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30733676.s2.e0" e2="DDI-PubMed.30733676.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30733676.s2.e0" e2="DDI-PubMed.30733676.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30733676.s2.e0" e2="DDI-PubMed.30733676.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30733676.s2.e1" e2="DDI-PubMed.30733676.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30733676.s2.e1" e2="DDI-PubMed.30733676.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30733676.s2.e1" e2="DDI-PubMed.30733676.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30733676.s2.e2" e2="DDI-PubMed.30733676.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30733676.s2.e2" e2="DDI-PubMed.30733676.s2.e3" /></sentence><sentence text=" Methods: The efficacy and pharmacokinetics of orally administered TB-2 (33"><entity charOffset="67-69" id="DDI-PubMed.30733676.s3.e0" text="TB-2" /></sentence><sentence text="3 mg/kg/day), BBR (66"><entity charOffset="14-17" id="DDI-PubMed.30733676.s4.e0" text="BBR" /></sentence><sentence text="7 mg/kg/day), and TB-2+BBR (100 mg/kg/day) were evaluated in spontaneously non-obese diabetic Goto-Kakizaki (GK) rats, and metformin (200 mg/kg/day) was used as a positive control"><entity charOffset="123-132" id="DDI-PubMed.30733676.s5.e0" text="metformin" /><entity charOffset="18-26" id="DDI-PubMed.30733676.s5.e1" text="TB-2" /><entity charOffset="23-31" id="DDI-PubMed.30733676.s5.e2" text="BBR" /><pair ddi="false" e1="DDI-PubMed.30733676.s5.e1" e2="DDI-PubMed.30733676.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30733676.s5.e1" e2="DDI-PubMed.30733676.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30733676.s5.e1" e2="DDI-PubMed.30733676.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30733676.s5.e2" e2="DDI-PubMed.30733676.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30733676.s5.e2" e2="DDI-PubMed.30733676.s5.e0" /></sentence><sentence text=" The comparative exposure of the parent drugs, timosaponin A3 (TB-2 metabolite), and M1-M5 (BBR metabolites) was quantified in the portal vein plasma (before hepatic disposition), liver, and systemic plasma (after hepatic disposition) of normal rats on single and combination treatments"><entity charOffset="47-61" id="DDI-PubMed.30733676.s6.e0" text="timosaponin A3" /><entity charOffset="63-76" id="DDI-PubMed.30733676.s6.e1" text="TB-2" /><entity charOffset="92-105" id="DDI-PubMed.30733676.s6.e2" text="BBR" /><pair ddi="false" e1="DDI-PubMed.30733676.s6.e0" e2="DDI-PubMed.30733676.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30733676.s6.e0" e2="DDI-PubMed.30733676.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30733676.s6.e0" e2="DDI-PubMed.30733676.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30733676.s6.e1" e2="DDI-PubMed.30733676.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30733676.s6.e1" e2="DDI-PubMed.30733676.s6.e2" /></sentence><sentence text=" Cooperative mechanism of TB-2 and BBR on intestinal absorption and hepatic metabolism was investigated in Caco-2 cells and primary hepatocytes, respectively"><entity charOffset="26-28" id="DDI-PubMed.30733676.s7.e0" text="TB-2" /><entity charOffset="35-37" id="DDI-PubMed.30733676.s7.e1" text="BBR" /><pair ddi="false" e1="DDI-PubMed.30733676.s7.e0" e2="DDI-PubMed.30733676.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30733676.s7.e0" e2="DDI-PubMed.30733676.s7.e1" /></sentence><sentence text=" Results: After a 6-week experiment, non-fasting and fasting blood glucose levels and oral glucose tolerance test results showed that TB-2+BBR treatments (100 mg/kg/day) displayed significantly anti-diabetic efficacy in GK rats, comparable to that on metformin treatments"><entity charOffset="67-74" id="DDI-PubMed.30733676.s8.e0" text="glucose" /><entity charOffset="91-98" id="DDI-PubMed.30733676.s8.e1" text="glucose" /><entity charOffset="251-260" id="DDI-PubMed.30733676.s8.e2" text="metformin" /><entity charOffset="134-142" id="DDI-PubMed.30733676.s8.e3" text="TB-2" /><entity charOffset="139-147" id="DDI-PubMed.30733676.s8.e4" text="BBR" /><pair ddi="false" e1="DDI-PubMed.30733676.s8.e0" e2="DDI-PubMed.30733676.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30733676.s8.e0" e2="DDI-PubMed.30733676.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30733676.s8.e0" e2="DDI-PubMed.30733676.s8.e3" /><pair ddi="false" e1="DDI-PubMed.30733676.s8.e0" e2="DDI-PubMed.30733676.s8.e4" /><pair ddi="false" e1="DDI-PubMed.30733676.s8.e0" e2="DDI-PubMed.30733676.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30733676.s8.e1" e2="DDI-PubMed.30733676.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30733676.s8.e1" e2="DDI-PubMed.30733676.s8.e3" /><pair ddi="false" e1="DDI-PubMed.30733676.s8.e1" e2="DDI-PubMed.30733676.s8.e4" /><pair ddi="false" e1="DDI-PubMed.30733676.s8.e1" e2="DDI-PubMed.30733676.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30733676.s8.e3" e2="DDI-PubMed.30733676.s8.e3" /><pair ddi="false" e1="DDI-PubMed.30733676.s8.e3" e2="DDI-PubMed.30733676.s8.e4" /><pair ddi="false" e1="DDI-PubMed.30733676.s8.e3" e2="DDI-PubMed.30733676.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30733676.s8.e4" e2="DDI-PubMed.30733676.s8.e4" /><pair ddi="false" e1="DDI-PubMed.30733676.s8.e4" e2="DDI-PubMed.30733676.s8.e2" /></sentence><sentence text=" However, no significant improvement was observed on TB-2 or BBR treatments alone"><entity charOffset="53-55" id="DDI-PubMed.30733676.s9.e0" text="TB-2" /><entity charOffset="61-63" id="DDI-PubMed.30733676.s9.e1" text="BBR" /><pair ddi="false" e1="DDI-PubMed.30733676.s9.e0" e2="DDI-PubMed.30733676.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30733676.s9.e0" e2="DDI-PubMed.30733676.s9.e1" /></sentence><sentence text=" Compared to single treatments, combination treatments led to the increased circulating levels of BBR by 107% in GK rats"><entity charOffset="98-100" id="DDI-PubMed.30733676.s10.e0" text="BBR" /></sentence><sentence text=" In normal rats, the hepatic exposure of BBR, timosaponin A3, and M1-M5 was several hundred folds higher than their circulating levels"><entity charOffset="46-60" id="DDI-PubMed.30733676.s11.e0" text="timosaponin A3" /><entity charOffset="41-54" id="DDI-PubMed.30733676.s11.e1" text="BBR" /><pair ddi="false" e1="DDI-PubMed.30733676.s11.e1" e2="DDI-PubMed.30733676.s11.e1" /><pair ddi="false" e1="DDI-PubMed.30733676.s11.e1" e2="DDI-PubMed.30733676.s11.e0" /></sentence><sentence text=" Co-administration also improved the levels in the plasma and liver by 41-114% for BBR, 141-230% for TB-2, and 12-282% for M1-M5"><entity charOffset="101-103" id="DDI-PubMed.30733676.s12.e0" text="TB-2" /><entity charOffset="83-85" id="DDI-PubMed.30733676.s12.e1" text="BBR" /><pair ddi="false" e1="DDI-PubMed.30733676.s12.e1" e2="DDI-PubMed.30733676.s12.e1" /><pair ddi="false" e1="DDI-PubMed.30733676.s12.e1" e2="DDI-PubMed.30733676.s12.e0" /></sentence><sentence text=" In vitro, the interaction between TB-2 and BBR was mediated by intestinal absorption, rather than hepatic metabolism"><entity charOffset="35-37" id="DDI-PubMed.30733676.s13.e0" text="TB-2" /><entity charOffset="44-46" id="DDI-PubMed.30733676.s13.e1" text="BBR" /><pair ddi="false" e1="DDI-PubMed.30733676.s13.e0" e2="DDI-PubMed.30733676.s13.e0" /><pair ddi="false" e1="DDI-PubMed.30733676.s13.e0" e2="DDI-PubMed.30733676.s13.e1" /></sentence><sentence text=" Conclusion: Combining TB-2 and BBR enhanced the anti-diabetic efficacy by increasing the in vivo variety of effective substances, including the parent compounds and active metabolites, and improving the levels of those substances through intestinal absorption"><entity charOffset="23-25" id="DDI-PubMed.30733676.s14.e0" text="TB-2" /><entity charOffset="32-34" id="DDI-PubMed.30733676.s14.e1" text="BBR" /><pair ddi="false" e1="DDI-PubMed.30733676.s14.e0" e2="DDI-PubMed.30733676.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30733676.s14.e0" e2="DDI-PubMed.30733676.s14.e1" /></sentence><sentence text=" This study is a new attempt to assess the effects of combined plant ingredients on diabetes by scientifically utilizing clinical experience of an herb pair" /><sentence text="" /></document>